Pfizer Inc. (NYSE:PFE) Position Increased by Claris Advisors LLC MO

Claris Advisors LLC MO boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 132.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,668 shares of the biopharmaceutical company's stock after purchasing an additional 14,647 shares during the period. Claris Advisors LLC MO's holdings in Pfizer were worth $650,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Boothe Investment Group Inc. increased its position in shares of Pfizer by 2.9% during the first quarter. Boothe Investment Group Inc. now owns 277,296 shares of the biopharmaceutical company's stock worth $7,027,000 after acquiring an additional 7,804 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in Pfizer by 25.6% during the 1st quarter. FNY Investment Advisers LLC now owns 16,910 shares of the biopharmaceutical company's stock worth $428,000 after purchasing an additional 3,446 shares during the last quarter. QRG Capital Management Inc. raised its position in shares of Pfizer by 95.8% in the 1st quarter. QRG Capital Management Inc. now owns 699,955 shares of the biopharmaceutical company's stock valued at $17,737,000 after purchasing an additional 342,476 shares in the last quarter. Sagespring Wealth Partners LLC boosted its stake in shares of Pfizer by 5.4% during the 1st quarter. Sagespring Wealth Partners LLC now owns 44,380 shares of the biopharmaceutical company's stock valued at $1,125,000 after buying an additional 2,264 shares during the last quarter. Finally, Murphy Pohlad Asset Management LLC grew its position in shares of Pfizer by 7.6% during the first quarter. Murphy Pohlad Asset Management LLC now owns 123,965 shares of the biopharmaceutical company's stock worth $3,141,000 after buying an additional 8,740 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE traded down $0.14 on Monday, hitting $24.40. The stock had a trading volume of 35,078,445 shares, compared to its average volume of 41,184,640. The company's 50-day moving average is $23.06 and its two-hundred day moving average is $24.95. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The stock has a market cap of $138.71 billion, a price-to-earnings ratio of 17.30, a P/E/G ratio of 0.64 and a beta of 0.57. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the company posted $0.82 EPS. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.05%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.